What Happens To Pfizer Stock If Patent Losses Outpace New Drugs?
What Happens To Pfizer Stock If Patent Losses Outpace New Drugs? Trefis
Covered in this story
Analyst targets on Pfizer
- Bank of America: $28.3 → $29 by Oct 2027 · Neutral via TIKR.com
- Cantor Fitzgerald: $28.3 → $28 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: $28.3 → $30 by Oct 2027 · Neutral via The Globe and Mail
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 49 stories mentioning Pfizer, the earliest published 30 Jun 2026.
Summary aggregated from Trefis's public RSS feed. The full reporting belongs to Trefis — please read it on their site.